Vertex Pharmaceuticals announces the reimbursement of ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) in Australia, a groundbreaking once-daily treatment for cystic fibrosis patients aged 6 and above with at least one responsive mutation in the CFTR gene.
This development is a significant step forward in Vertex's mission to innovate and improve the lives of those affected by cystic fibrosis. ALYFTREK, the fifth CFTR modulator in Australia, is the first once-daily option, simplifying treatment for patients. It targets the underlying cause of cystic fibrosis by enhancing the function of the faulty CFTR protein, offering hope to the approximately 3,200 Australians living with this condition.
The Pharmaceutical Benefits Scheme (PBS) listing of ALYFTREK is supported by global clinical trials and real-world evidence, ensuring its safety and efficacy. Patients and caregivers are advised to consult with their healthcare professionals to determine if ALYFTREK is suitable for them.
Cystic fibrosis, a life-shortening genetic disease, affects around 3,800 Australians. It progresses through multiple organs, impacting the lungs, liver, pancreas, GI tract, sinuses, sweat glands, and reproductive tract. ALYFTREK's mechanism of action involves improving the function of the defective CFTR protein, addressing the root cause of the disease.
Vertex's CF medicines are currently treating over 75,000 people with cystic fibrosis across more than 60 countries. The company's commitment to scientific innovation and transformative medicines is evident in its pipeline of investigational therapies for various serious diseases, including IgA nephropathy, neuropathic pain, and more.
ALYFTREK is subject to additional monitoring in Australia to ensure patient safety. Healthcare professionals are encouraged to report any adverse events to the TGA. The medication is contraindicated for those with hypersensitivity to its active substance or excipients, and precautions include monitoring liver function and transaminases. ALYFTREK should be used cautiously in patients with liver disease, and its efficacy may be reduced when co-administered with certain medications.
Common adverse effects include headache and diarrhea, with rash and elevated liver enzymes observed less frequently. Patients should refer to the Consumer Medicine Information for detailed side effects and precautions.
